Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors

Autor: van Eggermond, Anna M, Schaapveld, Michael, Janus, Cécile Pm, de Boer, Jan Paul, Krol, Augustinus Dg, Zijlstra, Josée M, van der Maazen, Richard Wm, Kremer, Leontien C, van Leerdam, Monique E, Louwman, Marieke Wj, Visser, Otto, De Bruin, Marie L, Aleman, Berthe Mp, van Leeuwen, Flora E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Přispěvatelé: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Radiotherapy, Other departments, CCA - Cancer Treatment and Quality of Life, Paediatric Oncology, CCA -Cancer Center Amsterdam, ARD - Amsterdam Reproduction and Development, CCA - Cancer Treatment and quality of life, Hematology, APH - Quality of Care
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Oncology
Male
Cancer Research
Neoplasms
Radiation-Induced
Colorectal cancer
medicine.medical_treatment
Prednisone/therapeutic use
Procarbazine
chemotherapy
radiation therapy
Neoplasms
Radiation-Induced/epidemiology
0302 clinical medicine
Risk Factors
Neoplasms
Antineoplastic Combined Chemotherapy Protocols
Taverne
Radiation-Induced/epidemiology
030212 general & internal medicine
Survivors
Hodgkin Disease/drug therapy
Netherlands
education.field_of_study
Incidence (epidemiology)
Hazard ratio
Neoplasms
Second Primary
Middle Aged
long-term complications
Hodgkin Disease
Antineoplastic Agents/administration & dosage
Vincristine
030220 oncology & carcinogenesis
Female
Colorectal Neoplasms
medicine.drug
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Adult
medicine.medical_specialty
Vincristine/therapeutic use
Vinblastine/therapeutic use
Colon
Population
Diaphragm
Second Primary/epidemiology
Antineoplastic Agents
Netherlands/epidemiology
colorectal cancer
Vinblastine
Mechlorethamine/therapeutic use
03 medical and health sciences
Bleomycin
Young Adult
SDG 3 - Good Health and Well-being
Internal medicine
medicine
Journal Article
Bleomycin/therapeutic use
Humans
Mechlorethamine
education
Colorectal Neoplasms/epidemiology
Chemotherapy
procarbazine
business.industry
Proportional hazards model
Rectum
Procarbazine/administration & dosage
medicine.disease
Radiation therapy
Doxorubicin
Clinical Study
second malignant neoplasm
Prednisone
Doxorubicin/therapeutic use
Neoplasms
Second Primary/epidemiology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Nuclear medicine
business
Hodgkin lymphoma
Follow-Up Studies
Zdroj: British Journal of Cancer
British Journal of Cancer, 117, 3, pp. 306-314
Van Eggermond, A M, Schaapveld, M, Janus, C P M, De Boer, J P, Krol, A D, Zijlstra, J M, Van Der Maazen, R W M, Kremer, L C, Van Leerdam, M E, Louwman, M W J, Visser, O, De Bruin, M L, Aleman, B M P & Van Leeuwen, F E 2017, ' Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors ', British Journal of Cancer, vol. 117, no. 3, pp. 306-314 . https://doi.org/10.1038/bjc.2017.177
British Journal of Cancer, 117(3), 306-314. Nature Publishing Group
British journal of cancer, 117(3), 306-314. Nature Publishing Group
British Journal of Cancer, 117(3), 306-314
British Journal of Cancer, 117(3), 306. Nature Publishing Group
van Eggermond, A M, Schaapveld, M, Janus, C P, de Boer, J P, Krol, A D, Zijlstra, J M, van der Maazen, R W, Kremer, L C, van Leerdam, M E, Louwman, M W, Visser, O, De Bruin, M L, Aleman, B M & van Leeuwen, F E 2017, ' Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors ', B J C, vol. 117, no. 3, pp. 306-314 . https://doi.org/10.1038/bjc.2017.177
British Journal of Cancer, 117, 306-314
ISSN: 0007-0920
DOI: 10.1038/bjc.2017.177
Popis: Contains fulltext : 177780.pdf (Publisher’s version ) (Open Access) BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens. METHODS: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses. RESULTS: After a median follow-up of 22.9 years, 55 patients developed CRC. The standardized incidence ratios (SIR) was 2.4-fold increased (95% confidence interval (95%CI) 1.8-3.2), leading to 5.7 excess cases per 10 000 patient-years. Risk was still increased 30 years after HL treatment (SIR: 2.8; 95%CI: 1.6-4.6). The highest (SIR: 6.5, 95%CI: 3.3-11.3) was seen for transverse colon cancer (15.0 (95%CI: 4.3-40.8) after inverted-Y irradiation). A prescribed cumulative procarbazine dose >4.2 g m-2 was associated with a 3.3-fold higher CRC risk (95%CI: 1.8-6.1) compared to treatment without procarbazine. Patients receiving >4.2 g m-2 procarbazine and infradiaphragmatic radiotherapy had a hazard ratio of 6.8 (95%CI: 3.0-15.6) compared with patients receiving neither treatment, which is significantly higher than an additive joint effect (Padditivity=0.004). CONCLUSIONS: Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose.
Databáze: OpenAIRE
Externí odkaz: